Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
April 29 2019 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
first quarter of 2019 on Monday, May 6, 2019. The Company will host
a webcast and conference call that day at 8:30 a.m. Eastern Time to
discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for
domestic callers or (765) 507-2618 for international callers and
referring to conference ID number 5697837. A live webcast of
the conference call will be available online in the Investors and
Media section of the Company’s website at
ir.minervaneurosciences.com. The archived webcast will be
available on the Company’s website beginning approximately two
hours after the event for 30 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva’s proprietary compounds include:
roluperidone (MIN-101), in clinical development for schizophrenia;
MIN-117, in clinical development for major depressive disorder
(MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical
development for insomnia and MDD; and MIN-301, in pre-clinical
development for Parkinson’s disease. Minerva’s common stock
is listed on the NASDAQ Global Market under the symbol
“NERV.” For more information, please visit
www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024